Company led recall-Zaditen eye drops

Thea Pharmaceuticals UK is recalling batch 4V64 of Zaditen 0.25 mg/ml, eye drops, solution 5ml
from all pharmacists and wholesalers with immediate effect.

The decision to recall has been taken as a precautionary measure due to the detection of an isolated
anomaly during manufacturing, which does not rule out the risk of microbial contamination of the
medicinal product.

drug alert date: 4/07/25

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Simvastatin 10mg Tablet, Crescent Pharma Ltd

Crescent Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of simvastatin 10 mg Tablets distributed by Alliance Healthcare UK.

MHRA Drug alert link: Class 4 Medicines Defect Notification: Simvastatin 10mg Tablet, Crescent Pharma Ltd, EL(25)A/33 - GOV.UK

MHRA drug alert date: 3/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email medinfo@crescentpharma.com, for reporting of side effects email safety@crescentpharma.com or telephone +44 1217901596.

For stock control enquiries please email Sean.McCaul@alliance-healthcare.co.uk

Class 4 caution in use-Erythromycin Stearate BP 250mg Tablets

Amdipharm UK Ltd has informed MHRA that the Patient information leaflet (PIL) in the cartons for the batch listed in this notification includes a superseded PIL.

MHRA Drug alert link: Class 4 Medicines Defect Notification: Erythromycin Stearate BP 250mg Tablets, Amdipharm UK Ltd, EL(25)A/32 - GOV.UK

MHRA drug alert date: 1/07/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email medicalinformation@advanzpharma.com, or telephone +44 (0) 208 588 9131

For stock control enquiries please email custcustomercare@advanzpharma.com or telephone 0208 588 9441

Class 3 recall-Tamoxifen 20mg Film-Coated Tablets

Wockhardt UK Limited is recalling a batch as a precautionary measure following the identification of a dissolution failure during stability testing.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-tamoxifen-20mg-film-coated-tablets-wockhardt-uk-ltd-el-25-a-slash-31?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=51a03b30-994a-4270-a2ee-77e56b55fcd8&utm_content=immediately

MHRA drug alert date: 30/06/25

Further Information

For medical information enquiries please email drug.safety@wockhardt.co.uk, or telephone 01978 661261 and ask for ‘drug safety’.

For stock control enquiries please email group_uk_csu@wockhardt.co.uk, or telephone 01978 661261and ask for ‘customer services’.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall – Omeprazole 20 mg/15 ml Oral Solution Active

We have received a Class 3 Recall from Glenmark Pharmaceuticals on Omeprazole 20 mg/15 ml Oral Solution

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-omeprazole-20-mg-slash-15-ml-oral-solution-glenmark-pharmaceuticals-europe-ltd-el-25-a-slash-30?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e78400fa-abcd-4b11-8293-0ab9b0eb4e68&utm_content=immediately

MHRA ref: DMRC-35139406

Reason: Glenmark Pharmaceuticals Europe Ltd is recalling a specific batch of Omeprazole Oral Solution as a precautionary measure due to an investigation following a customer complaint indicating precipitation and discoloration of the product in the bottles. A root cause has identified that this is a result of an inadequate assembly of the plunger stem and the cup which could lead to a premature mixing of the two components of the medicinal product.

Please can you ensure that your stores quarantine the product listed below. 

Further Information

For medical information enquiries please use the following options by phone +44 08004 580 383 or email medical_information@glenmarkpharma.com

For stock control enquiries please email orders.uk@glenmarkpharma.com

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 recall-PI Depo-Medrone 80mg/2mL suspension for injection

A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-depo-medrone-80-mg-in-2-ml-maxearn-limited-el-25-a-slash-29?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=bc49e601-5d15-4f12-b3b9-be4fddb3db61&utm_content=immediately

MHRA drug alert date 25/06/25

Further Information

For all medical information enquiries and information on this product, please email maxearnqa@maxearn.co.uk or telephone 01204 471 269.

For stock control enquiries please email maxearnqa@maxearn.co.uk or telephone 01204 471 269.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall-Kimmtrak 200 micrograms/mL concentrate for solution for infusion

Immunocore Limited is recalling the batches listed below as a precautionary measure. The recall is due to a decrease in potency identified during stability testing. All other stability test results remain within specification.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-kimmtrak-200-micrograms-slash-ml-concentrate-for-solution-for-infusion-immunocore-limited-el-25-a-slash-28?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=45800870-bf29-4be7-9270-c1a645ebf0b7&utm_content=immediately

MHRA drug alert date 25/06/25

Further Information

For all medical information enquiries and information on this product, please email medinfo.eu@immunocore.com, or telephone +442076645100 (local toll) or +00 800-74451111 (toll-free).

For stock control enquiries please email john.sandford@immunocore.com, or telephone +00353(0)858515258.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Alphega Pharmacy UK Elevate Convention 2025: Leading the Future of Pharmacy Through Innovation, AI, and Patient-Centred Care

Alphega Pharmacy brought together more than 200 independent pharmacy professionals, partners and thought leaders for its annual conference this weekend in Birmingham. The event, hosted at the Hilton Hotel on 22 June, explored the latest in healthcare innovation, operational excellence and patient care, as well as discussions of the changing pharmacy landscape and embracing technological innovation. Attendees shared practical insights and real-world solutions shaping the future of independent pharmacy in the UK.

The conference featured a lineup of notable speakers from Perrigo, Serve First, Reckitt and Kenvue, as well as Dr Zubir Ahmed MP. Alongside this, breakout sessions took place focused on supplier perspectives, from smarter solutions from working, to elevating community pharmacists and helping patients quit smoking. Sessions also included practical case studies from Alphega members and suppliers.

As the role of community pharmacy continues to expand, the Alphega Convention acts as a catalyst for knowledge-sharing and collaboration, helping members stay ahead of clinical, operational and digital changes in primary care. Attendees left with tools and new strategies – from embracing digital solutions to enhancing patient engagement – that provided practical insights to streamline operations and strengthen their role as frontline healthcare providers within their communities.

Mandeep Mudhar, Head of Alphega, said: “This year’s Alphega Pharmacy UK Elevate Convention 2025 showed just how much opportunity exists for pharmacies that embrace innovation and patient-first thinking. It was fantastic to see so many passionate pharmacy professionals come together to share ideas and look ahead to an exciting future.”

Dr Zubir Ahmed, MP for Glasgow South West, said: “Alphega Pharmacy UK Elevate Convention was a strong reflection of the strength of community pharmacy and its vital role in shaping the future of healthcare. Alphega members are instrumental in driving the shift from hospital-based care to more community-focused services. The conference was a landmark event and I was honoured to be the keynote Westminster speaker.”

Alliance Healthcare Teams Complete 300 Mile Cross-Border Charity Cycle Challenge

Eight Alliance Healthcare team members have completed grueling 300 mile cross-border Tour D’Alliance 2025 challenge, raising over £55,000 for Theodora Children’s Charity.

From 13 to 15 June, participants from the UK and France cycled from Chessington, Surrey to Alliance Healthcare France HQ in Paris. The cross-border challenge not only celebrated international teamwork but also raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Matt Addison, VP Operations, Alliance Healthcare, who created the Tour D’Alliance series back in 2019 said: “This year we took the challenge international, and the sponsorship and support has been incredible. We were determined to raise as much as possible to help young children and their families during the most difficult times. Over £55,000 raised for Theodora Children’s Charity is an amazing amount and I am proud of the team who knew that with every painful pedal, we were doing our bit to help a very worthy cause.”

Ellen Blessington, Senior Community and Communications Fundraiser said: “We are incredibly grateful to have been supported in this year’s Tour D’Alliance. Being ill and needing medical treatment is difficult at any point in life, but when you are a child, it can be particularly confusing and frightening. Thanks to the cyclists taking on the challenge of 300 miles, over 2,400 children will receive a magical Giggle Doctor visit, helping reduce their stress and anxiety, create opportunities for play and transform their hospital experience. From all of us at Theodora Children’s Charity, including our Giggle Doctors, our heartfelt thanks go to the cyclists, drivers, sponsors and everyone who made this challenge possible!”

Teams across Alliance Healthcare supported the challenge with a teddy bear plush toy photo competition, summer garden buffet and breakfast party send-off at the Chessington site. Tour D’Alliance 2025 showcased the physical strength and spirit of the participants, reflecting Alliance Healthcare’s commitment to creating healthier futures through charitable fundraising and collective action.

Special thanks to all our sponsors and generous supporters, in particular: LCM and Mertrux. Since its origin Tour D’Alliance has now raised over £230,000 for charities.
 

Class 2 recall-PI Inhixa 12,000IU (120mg)/0.8mL solution for injection

Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-inhixa-12000iu-120mg-slash-0-dot-8ml-solution-for-injection-maxearn-limited-el-25-a-slash-27?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=225b3c3d-411e-4f22-9b63-30117bf0dac8&utm_content=immediately

MHRA drug alert date 12/06/25

Further Information

For all medical information enquiries and information on this product, please email eupvg@genreg.eu or telephone 020 7201 0421.

For stock control enquiries please email info@genesis-pharma.com or telephone 0207 201 0400.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.